Berenberg Bank Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by equities researchers at Berenberg Bank in a research report issued on Monday,MarketScreener reports.

A number of other brokerages also recently weighed in on BNTX. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, November 12th. Bank of America dropped their target price on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. UBS Group raised their price target on shares of BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $135.20.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $102.53 on Monday. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.65 billion, a PE ratio of -64.08 and a beta of 1.54. The firm has a fifty day simple moving average of $102.92 and a 200 day simple moving average of $104.94. BioNTech has a twelve month low of $81.20 and a twelve month high of $129.27.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The business had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in BNTX. Krensavage Asset Management LLC lifted its position in shares of BioNTech by 8.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 79,366 shares of the company’s stock worth $7,827,000 after buying an additional 5,984 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of BioNTech by 10.8% during the third quarter. CANADA LIFE ASSURANCE Co now owns 9,552 shares of the company’s stock valued at $935,000 after acquiring an additional 933 shares during the last quarter. XTX Topco Ltd bought a new stake in BioNTech during the third quarter worth $1,459,000. Alyeska Investment Group L.P. purchased a new position in BioNTech in the third quarter worth $5,687,000. Finally, Scientech Research LLC bought a new position in BioNTech in the 3rd quarter valued at $517,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.